The drug, ATryn has already been approved in Europe. Up until now the drug has been created from blood from human donors. The drug is used to prevent blood clots and would be used during surgery given via an IV, and would not replace normal prescribed blood thinners taken as a normal treatment...
Will Plavix be the next drug up for a genetic test? There are not many alternative drugs either that could easily replace the functionality of Plavix, it is a blood thinner. One idea would be to monitor patients with poor liver or kidney metabolization. as suggested here , a blog written...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
01-02-2009
Filed under:
Filed under: Medically Related, Technology, Insurance, Pharma/FDA News, Physician, personalized medicine, DNA, Genomics, healthcare, Health IT, Cardiology, Biotech, FDA, Information Overload, Pharmacogenomics, Sequencing, FDA warnings, Plavix
Warfarin is the second-most-likely drug, to cause adverse events requiring hospitalization. The use of warfarin sensitivity testing in the U.S. could avoid 85,000 serious-bleeding incidents. More in the way of personalized medicine and if you were a patient determined to have an adverse reaction...
The National Institute of Health sees the value of genetic profiles and is funding additional research. Duke University was the first client to use Expression Analysis and collaborates with the FDA and pharma for electronic submissions of data in an effort to accelerate drugs and diagnostics though...